Researcher.Life Logo

Expert Opinion on Drug Safety : Impact Factor & More

eISSN: 1744-764XpISSN: 1474-0338

Aims and Scope of Expert Opinion on Drug Safety

Expert Opinion on Drug Safety is a monthly peer-reviewed medical journal publishing review articles on all aspects of pharmacovigilance and original papers on the clinical implications of drug treatment safety issues. It was established in 2002 and is published by Informa. The editor-in-chief is Roger McIntyre (University of Toronto). Less

Key Metrics

CiteScore
6.1
Eigenfactor
0.005 - 0.01
H-Index
81
Impact Factor
< 5
SJR
Q2Pharmacology (medical)
SNIP
1.17
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Expert Opinion on Drug Safety

Expert Opinion on Drug Safety Journal Specifications

Overview
Publisher TAYLOR & FRANCIS LTD
Language English
Frequency Bi-monthly
General Details
LanguageEnglish
FrequencyBi-monthly
Publication Start Year2002
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Expert Opinion on Drug Safety ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Expert Opinion on Drug Safety

Could anticholinergics accelerate ALS progression? A critical perspective on drug safety and disease vulnerability.
  • 30 Jun 2026
  • Expert opinion on drug safety
Safety profile of teprotumumab-trbw, the first and only FDA-approved treatment for thyroid-associated ophthalmopathy
  • 26 Jun 2026
  • Expert Opinion on Drug Safety
A systematic review and meta-analysis of safety and efficacy parameters of sotatercept in the therapy of pulmonary arterial hypertension
  • 12 Jun 2026
  • Expert Opinion on Drug Safety
Tirzepatide data: safety first is safety always!
  • 4 Jun 2026
  • Expert Opinion on Drug Safety
An update on the safety of biologics for the treatment of psoriasis
  • 21 May 2026
  • Expert Opinion on Drug Safety
Recent advances in trastuzumab and its antibody-drug conjugates-related liver injury
  • 18 May 2026
  • Expert Opinion on Drug Safety
Could anticholinergics accelerate ALS progression? A critical perspective on drug safety and disease vulnerability.
  • 30 Jun 2026
  • Expert opinion on drug safety
Safety profile of teprotumumab-trbw, the first and only FDA-approved treatment for thyroid-associated ophthalmopathy
  • 26 Jun 2026
  • Expert Opinion on Drug Safety
A systematic review and meta-analysis of safety and efficacy parameters of sotatercept in the therapy of pulmonary arterial hypertension
  • 12 Jun 2026
  • Expert Opinion on Drug Safety
Tirzepatide data: safety first is safety always!
  • 4 Jun 2026
  • Expert Opinion on Drug Safety
An update on the safety of biologics for the treatment of psoriasis
  • 21 May 2026
  • Expert Opinion on Drug Safety
Recent advances in trastuzumab and its antibody-drug conjugates-related liver injury
  • 18 May 2026
  • Expert Opinion on Drug Safety

FAQs on Expert Opinion on Drug Safety